The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease

References

• Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13: 504–10
   Google Scholar
• McClellan W, Tran LT, the PAERI Study Group. The prevalence of anemia in patients with chronic kidney disease: final results from the PAERI study. J Am Soc Nephrol 2002;13:461 [abstract:SA-PO955]
   Google Scholar
• Fink JC, Blahut SA, Reddy M, Light PD. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348–55
   PubMed Web of Science ®Google Scholar
• Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884–90
   PubMed Web of Science ®Google Scholar
• Luthi JC, Flanders WD, Burnier M, et al. Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients. BMC Nephrol 2006; 7:doi:10.1186/1471-2369-7-3
   Google Scholar
• Evans RW, Rader B, Manninen DL, et al. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. J Am Med Assoc 1990;263:825–30
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:S182–S238
   Web of Science ®Google Scholar
• Epoetin Alfa (EPREX®) product package insert. Available from: http://www.janssen-ortho.com/JOI/pdf_files/Eprex_E.pdf [last accessed 09/27/06]
   Google Scholar
• Darbepoetin Alfa (Aranesp®) product package insert. Available from: http://www.aranesp.com/pdf/aranesp_PI.pdf [last accessed 09/27/06]
   Google Scholar
• Stone WJ, Graber SE, Krantz SB, et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. Am J Med Sci 1988; 296:171–9
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996;7:763–73
   PubMed Web of Science ®Google Scholar
• Locatelli F, Olivares J, Walker R, et al. Novel erythopoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741–7
   PubMed Web of Science ®Google Scholar
• Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004;60:392–405
   Google Scholar
• Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000;11: 335–42
   PubMed Web of Science ®Google Scholar
• Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362–9
   PubMed Web of Science ®Google Scholar
• Mahajan S, Boulton H, Gokal R. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. J Nephrol 2004;17:687–92
   Google Scholar
• Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology 2004;9:223–8
   PubMed Web of Science ®Google Scholar
• Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains haemoglobin concentration at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004;19:1224–30
   PubMed Web of Science ®Google Scholar
• Aljama P, Bommer J, Canaud B, et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001;16:22–8
   PubMed Web of Science ®Google Scholar
• Locatelli F, Olivares J, Walker R, et al. Novel erythopoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741–7
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110–8
   PubMed Web of Science ®Google Scholar
• Varenterghem Y, Bàràny P, Mann JFE, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167–75
   PubMed Web of Science ®Google Scholar
• Gokal R. Darbepoetin alfa maintains hemoglobin concentrations at reduced dose frequencies in patients receiving peritoneal dialysis. American Society of Nephrology Renal Week, San Diego, California, 2003 [abstract:SU-PO1066]
   Google Scholar
• Haller H. Darbepoetin alfa raises previously suboptimal hemoglobin concentration in renal anemia patients. American Society of Nephrology Renal Week, San Diego, California, 2003 [presentation]
   Google Scholar
• Jenkins KJ, John RI, Stevens PE, et al. Aranesp® (darbepoetin alfa) in the management of anaemia in dialysis patients receiving high dose erythropoietin (rHuEPO). American Society of Nephrology Renal Week, San Diego, California, 2003 [abstract: SA-PO904]
   Google Scholar
• Jenkins KJ, Benneth LI, Monk A, et al. Intravenous Aranesp® (darbepoetin alfa) in the management of anaemia of haemodialysis patients previously receiving subcutaneous erythropoietin (rHuEPO). American Society of Nephrology Renal Week, San Diego, California, 2003 [abstract: SA-PO735]
   Google Scholar
• Martinez-Castelao A, Bestard O. Anemia treatment with darbepoetin alfa in chronic renal hemodialysis patients who did not respond to recombinant human erythropoietin (rHuEPO) treatment. American Society of Nephrology Renal Week, San Diego, California, 2003 [abstract:PUB052]
   Google Scholar
• Raymond CB, Bernstein KN, Skwarchuk DE, et al. Conversion from erythropoietin to darbepoetin for management of anemia of chronic kidney disease: The Manitoba experience. American Society of Nephrology Renal Week, St-Louis, Missouri, 2004 [abstract:F-PO22]
   Google Scholar
• Shalansky KF, Jastrzebski J. Complete switch to darbepoetin in a hemodialysis unit. Niagara Falls (ON); Canadian Association of Nephrology Nurses and Technologists; 2004 [presentation]
   Google Scholar
• Coyne DW, Ling BN, Toto R, et al. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administrated at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO). American Society of Nephrology Renal Week, 2000 [abstract A1380]
   Google Scholar
• Pussel BA, Walker R. Comparison of doses of epoetin alfa and darbepoetin alfa required for maintenance of hemoglobin levels in a naturalistic setting. American Society of Nephrology Renal Week, St-Louis, Missouri, 2004 [abstract:PUB291]
   Google Scholar
• Jacobs C, Frei D, Perkins AC. Key actors dosage of epoetin therapy and resulting hemoglobin levels in dialysis patients: European survey of anemia management (ESAM). American Society of Nephrology Renal Week, St-Louis, Missouri, 2004 [abstract:SU-PO1064]
   Google Scholar
• Horl WH, Holzer H, Mayer GJ. Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study. Wien Klin Wochenschr 2002;114:967–71
   Google Scholar
• Del Vecchio L, Villa G, Carraro G, et al. Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO). G Ital Nefrol 2004;21:259–66
   PubMedGoogle Scholar
• Molina M, Garcia Hernandez MA, Navarro MJ, et al. Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha. Nefrologia 2004;24:564–71
   PubMed Web of Science ®Google Scholar
• Molina M, Garcia Hernandez MA, Navarro MJ, et al. Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa. Nefrologia 2004;24:54–9
   PubMed Web of Science ®Google Scholar
• Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005;34:215–20
   PubMed Web of Science ®Google Scholar
• Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. Br Med J 2003;326:1083–4
   PubMed Web of Science ®Google Scholar
• Régie de l’assurance maladie du Québec (RAMQ). Liste des médicaments par marque de commerce. Available from: http://www.ramq.gouv.qc.ca/fr/professionnels/listmed/pdf/modification/marque_commerce.pdf [last accessed 09/27/06]
   Google Scholar